Indução oral rápida de tolerância a alopurinol: um relato de caso
Rapid induction of oral tolerance to allopurinol: a case report
Caroline Rosa Emergente Coutinho; Larissa Oliveira F. Silva-Lima; Mariana S. Soares Peron; Bruna C. Valdivieso; Erika P. Souza; Eli Mansour
Resumo
O alopurinol, de uso contínuo oral, é o tratamento de escolha para os distúrbios hereditários do glicogênio. Apesar de não ser comum, a reação de hipersensibilidade ao alopurinol se torna um problema quando esta é a única medicação disponível para o controle da doença de base. Nestes casos, a dessensibilização é uma alternativa viável. No presente relato, descrevemos o caso de um paciente com diagnóstico de doença de depósito de glicogênio tipo I, com exantema pruriginoso generalizado ao alopurinol, tratado com um protocolo de dessensibilização oral acelerado. Este tratamento permitiu o uso contínuo deste medicamento sem novas reações em longo prazo.
Palavras-chave
Abstract
Continuous oral allopurinol use is the first-line treatment for hereditary glycogen disorders. While hypersensitivity reactions to allopurinol are uncommon, they can pose challenges when this medication is the only available option for the long-term treatment of the underlying disorder. In such cases, desensitization emerges as a viable alternative. We report the case of a patient with glycogen storage disease type I who developed a generalized pruritic rash due to allopurinol. Drug intolerance was successfully managed using a rapid oral desensitization protocol, which allowed an uneventful long-term use of allopurinol.
Keywords
References
1. Hannah WB, Derks TGJ, Drumm ML, Grünert SC, Kishnani PS, Vissing J. Glycogen storage diseases. Nat Rev Dis Primer. 2023;9:46.
2. Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol. 2007;13:2541-53.
3. Kishnani PS, Austin SL, Abdenur JE, Arn P, Bali DS, Boney A, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014;16:e1-e29.
4. Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol. 2020;32:71-9.
5. Danve A, Sehra ST, Neogi T. Role of diet in hyperuricemia and gout. Best Pract Res Clin Rheumatol. 2021;35:101723.
6. Chou JY, Matern D, Mansfield BC, Chen Y-T. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med. 2002;2:121-43.
7. Wang C-W, Dao R-L, Chung W-H. Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions. Curr Opin Allergy Clin Immunol. 2016;16:339-45.
8. Halevy S, Ghislain P-D, Mockenhaupt M, Fagot J-P, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25-32.
9. Jarjour S, Barrette M, Normand V, Rouleau JL, Dubé M-P, de Denus S. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review. Pharmacogenomics. 2015;16:755-67.
10. Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74:1457-71.
11. Pichler WJ. The important role of non-covalent drug-protein interactions in drug hypersensitivity reactions. Allergy. 2022;77:404-15.
12. Dykewicz MS, Lam JK. Drug Hypersensitivity Reactions. Med Clin North Am. 2020;104:109-28.
13. Fleisher TA. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Introduction. J Allergy Clin Immunol Pract. 2020;8:S1-S2.
14. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001;44:231-8.
15. Schumacher MJ, Copeland JG. Intravenous desensitization to allopurinol in a heart transplant patient with gout. Ann Allergy Asthma Immunol. 2004;92:374-6.
16. Calogiuri G, Nettis E, Di Leo E, Foti C, Ferrannini A, Butani L. Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules. Inflamm Allergy Drug Targets. 2013;12:19-28.
17. Dursun AB, Sahin OZ. Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report. Allergy Asthma Clin Immunol. 2014;10(1):52.
18. Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology. 2013;52:2031-40.
19. Soares J, Caiado J, Lopes A, Pereira BM. Allopurinol Desensitization: A Fast or Slow Protocol? J Investig Allergol Clin Immunol. 2015;25:295-7.
20. Nitti F, Fumagalli M, Incorvaia C. Rush desensitization to allopurynol. Allergy. 2003;58:690.
21. Toker O, Tvito A, Rowe JM, Ashkenazi J, Ganzel C, Tal Y, et al. Rapid oral allopurinol desensitization in a patient with chronic myeloid leukemia. Isr Med Assoc J. 2014;16:461-2.
Submitted date:
12/01/2023
Accepted date:
12/26/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email